Company patents
Daewoong Pharmaceutical Co., Ltd.
Daewoong Pharmaceutical Co., Ltd. demonstrates a strong and consistent focus on "Pharmaceutical Preparations," accounting for 61.2% of its portfolio, with a notable 60.0% YoY growth in 2024, although showing a slight decline so far in 2026. Surprisingly, despite its core pharma focus, the company is also rapidly expanding its patent activity in "Pharmacy Containers / Devices," with a 100.0% YoY growth in 2026, indicating an emerging interest in medical device integration alongside its drug development.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
49 US filings (since 2023) · 11 categories · 12 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Devices and adapters that enable the sterile and secure transfer of liquids, such as medications or diluents, between containers (vials, syringes, IV bags) while minimizing exposure to contaminants or air.
Mechanical or electromechanical systems designed for precise, often self-administered, delivery of medicaments, including features for dose setting, needle insertion/retraction, and safety mechanisms to prevent premature activation.
Compounds, often featuring metal chelators or specific labeling moieties, designed for use in medical imaging techniques like Positron Emission Tomography (PET) or for radionuclide therapy, enabling diagnostic visualization or targeted radiation treatment.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Modifying microorganisms, plant cells, or animal cells through genetic engineering to enhance or enable the biosynthesis of target compounds, often involving metabolic pathway engineering.
Patents
Showing 1-10 of 10
API Solid Form Engineering